Atezolizumab Survival Advantage Continues To Be Seen in Frontline PD-L1–High NSCLC
January 31st 2021Multiple key efficacy end points continue to favor atezolizumab versus chemotherapy for patients with PD-L1–high, wild-type nonsquamous or squamous non–small cell lung cancer in the first line, according to a phase 3 trial follow-up.
Relapsed/Refractory Metastatic NSCLC Tumors Respond to Datopotamab Deruxtecan in Early Trial
January 31st 2021The investigational TROP-2–directed antibody-drug conjugate datopotamab deruxtecan will move forward in the treatment of relapsed/refractory non–small cell lung cancer, according to results from the 2020 World Conference on Lung Cancer Singapore.
Patients With Pretreated SCLC Have Improved Outcomes When Apatinib is Added to Chemo
January 30th 2021Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.
Trastuzumab Deruxtecan Shows Antitumor Activity for Patients with HER2-Overexpressing NSCLC
January 29th 2021Trastuzumab deruxtecan treatment demonstrated strong antitumor activity for patients with HER2-overexpressing NSCLC, regardless of HER2 expression levels, according to interim findings from the phase 2 DESTINY Lung-01 trial.
Helpful Markers for Immunotherapy Response May Lie With Mutations, irAEs
January 28th 2021Results from the 2020 World Conference on Lung Cancer Singapore demonstrated the feasibility of using STK11 mutations and immune-related adverse events as response predictors in patients with non–small cell lung cancer.
Further Patient Education by Clinicians Is Necessary to Facilitate Better Decision Making
January 28th 2021“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.
Pembrolizumab Combo Continues to Drive OS Benefit in Nonsqamous NSCLC Versus Chemotherapy Alone
January 28th 2021Supporting previously reported data, updated results of the phase 3 KEYNOTE-189 trial indicate that overall survival is significantly improved when pembrolizumab is added to platinum-based chemotherapy in the frontline treatment of patients with metastatic nonsqamous NSCLC.
Can This Biomarker-Based Screening Identify More Early-Stage Lung Cancers?
September 17th 2019A new study presented at the International Association for the Study of Lung Cancer's 2019 conference may have found a model for lung cancer screening which improves on lung cancer screening guidelines from the U.S. Preventive Services Task Force.
Extending Survival in Extensive-Stage Small-Cell Lung Cancer
September 11th 2019In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.
Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities
September 10th 2019Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.
Is Tumor Mutational Burden a Useful Predictor of NSCLC Therapy Efficacy?
September 10th 2019Data presented at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer suggested tumor mutational burden may not be associated with the efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy.
Camrelizumab Plus Chemo Considered as New First-Line Therapy
September 6th 2019Findings from the upcoming International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer show camrelizumab and chemotherapy showed survival benefits for patients with metastatic or otherwise advanced non-squamous non–small-cell lung cancer.